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Dr Nicholas G. Smedira (Cleveland, Ohio). Dr Quintana,
excellent presentation. I would like the guests to know that Dr
Quintana is a Fellow at the Mayo Clinic from Barcelona.
I would like to congratulate you on a great presentation, it was a
well-done report, and I congratulate the surgeons from Mayo
Clinic, who have performed>2000 myectomies with a<1% recur-
rence rate. This shows that in expert hands this operation is very
safe and reliable.
I have 2 questions that are mainly technical. You talk about the
length; you mentioned the depth of the resection specimen. The
question I am often asked and that I was asked on Saturday, is
how do you determine this, how do you determine how far down
you go, especially when you have SAM with midventricular
obstruction? How do you determine the thickness of the resection
specimen? Also, you did not mention in the talk or in the report
about the width of your resection. So, could you give us an idea
of how you make those determinations both by echocardiography
and intraoperatively?
Dr Quintana. Thank you, Dr Smedira, for your comments. I
think both questions can be answered through the same concept.The Journal of Thoracic and CaAs we said, usually a scar lesion is present and that can guide
the resection area. We always study the echocardiogram preoper-
atively and determine the thickness of the intraventricular septum
and that gives us an idea of how much we can resect. Usually it is
not less than 1 cm.
Also, we want to make a point here. Usually when a patient has
just had an inadequate length of excision at the previous operation,
the commonmistake has been to perform the myectomy just below
the aortic valve, which will lead to ventricular septal defect crea-
tion. This emphasizes the need for the myectomy to be continued
down below and toward the LV apex.
In terms of the width, we guide the resection by studying the
scar tissue and having an idea of where the point of obstruction is.
Dr Smedira. In the small number of patients who have had
recurrence of the obstruction, as I understand it, they did not
have a provocable gradient in your hands during the first operation.
Dr Quintana. That is true.
Dr Smedira. Also, you measured the septal thickness, and no
growth was found. So, it does not regrow, but this suggests, indi-
rectly, that too much septum had been left at the first operation.
After seeing that, what would you do differently now to try and
avoid that very small number of patients who had had an inade-
quate resection? Any difference? Are you doing direct pressure
measurements, do you think it was missed on the echocardiogram,
or did you not take enough muscle?
Dr Quintana. This series of patients had undergone intraoper-
ative direct measurements by needles placed on the ascending
aorta and the left ventricle.We are still uncertain why the measure-
ments did not detect these residual gradients after the initial myec-
tomy. There could be several speculations such as that after a pump
run and crossclamp time, eventually the myocardium might be
stunned, or the needles might have been be in the wrong place.
But we are unsure about that.
The conclusion we have made from these findings is that we
must systematically measure the gradients, that is something we
already do, and perhaps pay more attention to any residual signif-
icant septal thickness, reviewed on the echocardiogram at surgery.
Dr Daniel H. Drake (Traverse City, Mich). Again, I congratu-
late you on a spectacular series.
We plan our myectomies using axial echocardiography. We
determine the length and depth of the resection from a carefully
defined long-axis view, with a goal of leaving a residual septal
thickness of approximately 1 cm. In your opinion, is that
reasonable?
Dr Quintana. That has been described previously in the series
from the Mayo Clinic. At least 1 cm should be left in the septum to
prevent any potential ventricular septal defect creation, even after
surgery.
Dr Drake. Thank you.
Dr Gilles D. Dreyfus (Monte Carlo, Monaco). I want to
congratulate you on your presentation. I am, however, a bit sur-
prised that you hardly mentioned the mitral valve as a major
component of HCM. When you have SAM and a mitral valve
that is regurgitant, in the series I have done, with a number that
is far less than that at theMayo Clinic but still a significant number,
about 20, 25, we have always treated the mitral valve. SAM is
created by a posterior leaflet that is too high and covers the septum
and anterior leaflet. Not only that, but once you have trimmed the
septum through the aortic valve, if you detach the anterior leaflet ofrdiovascular Surgery c Volume 148, Number 3 915
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Dthe mitral valve, you can resect the septum, because you perfectly
align with the septum. Thus, you treat, not only the muscle, but
also the mitral valve by extending the anterior leaflet and pushing
the coaptation point backward, away from the septum.
So I am a bit surprised, because, really, if I wanted to be a bit
provocative, I would say that HCM is nearly a mitral valve disease
and hardly a muscle disease, and you are treating this just through
the muscle. So would you comment, please, on that. Thank you.
Dr Quintana. Thank you for your comments. I am happy that
you brought up this point. This is an important concept, and it is
usually mentioned.
We see the issue the other way around. We think that the mitral
valve regurgitation is a problem secondary to septal hypertrophy.
We have not seen problems with mitral regurgitation due to
SAM after resecting the hypertrophic septum that was causing
the obstruction. So, usually if myectomy is appropriate, the mitral
valve regurgitation will resolve, except if intrinsic mitral valve dis-
ease is present, such as degenerative disease or whatever. However,
if the mitral valve is structurally normal, nothing needs to be done
on the mitral valve, just an appropriate myectomy.
DrMarc Ruel (Ottawa, Ontario, Canada).One more comment
and question about refractory SAM. What has worked well in our
hands has been to use an edge-to-edge repair, or an Alfieri stitch, if
you will, with excellent results.
Returning to your series, 88% of patients had SAM. In some
cases, the diseasewas more than just hypertrophy but also included916 The Journal of Thoracic and Cardiovascular Surgdistortion of the left ventricle and the relationship of the
mitral valve to the septum. Did you use the Alfieri repair in your
series?
DrQuintana. Thank you very much. None of these patients had
undergone an Alfieri procedure. Only 4 patients underwent mitral
valve repair for intrinsic mitral valve disease, and that was resec-
tion of prolapsing segments and, eventually, a protective
annuloplasty.
Dr Leonard N. Girardi (New York, NY). Dr Quintana, I have 1
question. If you consider the 20 patients from Mayo, it was about
3.5 years from the first operation to the second. If you review their
initial echocardiograms coming out of the operating room, what
sort of LVOT gradients and how much mitral regurgitation did
they have coming out of the operating room after their first opera-
tion? Howmuch should we tolerate before we reclamp, go back in,
and do something else about the mitral valve, as was just
mentioned, or should we do some more resection?
Dr Quintana. Thank you for your question. These patients did
not have systolic anterior motion detected just after myectomy in
the operating room nor a gradient detected by direct needle place-
ment. Thus, we still do not quite understand why we were not able
to detect these persistent gradients. We have not seen muscle re-
growth, but I think if any significant systolic anterior motion and
associated mitral regurgitation is present, anything, probably,
more than mild mitral regurgitation in the context of SAM, it
should probably be reassessed surgically.ery c September 2014
